Skip to Content

Are you based in North America? If yes, switch to our North American website →

IGH/CCND1 Translocation, Dual Fusion

Applications
haematology
Catalogue Numbers
LPH 021 (10 tests)
LPH 021-S (5 tests)

Although translocations involving IGH and CCND1 (BCL1) were initially reported in B-CLL patients, the rearrangement is now considered to be a hallmark of mantle cell lymphoma (MCL).

Reciprocal translocations involving the IGH and CCND1 (previously known as BCL1) loci, t(11;14)(q13;q32), have been reported in B-CLL patients1. The involvement of the CCND1 (Cyclin D1) gene was initially reported from a cloning study looking at the breakpoints of the translocation. However, it is likely that the initial diagnosis on the samples used for the study should have been mantle cell lymphoma (MCL). The CCND1/IGH probe for detection of t(11;14) has been recommended by the British Committee for Standards in Haematology to enable atypical B-CLL patients to be distinguished from possible MCL patients2.

References

1. Brizard et al., Leuk Lymphoma 1997;25(5-6):539-43

2. Parker et al., Best Practice in Lymphoma Diagnosis and Reporting; Specific disease appendix 2010, p5

Microscope Images

IGH CCND1 Translocation Dual Fusion magnified
Area of Interest*
CLL

Disclaimer

This product is intended to be used on Carnoy’s solution (3:1 methanol/acetic acid) fixed haematological samples.

*Disease information supported by the literature and is not a reflection of the intended purpose of this product.